Sign In

Clayton Rabideau

-

Clayton Rabideau is the Founder and CEO of SynTensor, a company focused on building foundation models for cellular biology.14 He holds a PhD in Chemical Engineering and Biotechnology from the University of Cambridge, where he conducted research on computational synthetic biology.2

Rabideau founded SynTensor in January 2019 and has been leading the company for over 5 years.1 The company's mission is to develop an accurate mechanistic model of human physiology, making complex biological processes tractable at scale for scientists, drug developers, and clinicians.13

SynTensor's platform simulates complex metabolic interactions within cells across all tissues, generating causal hypotheses for drug efficacy and systemic toxicity.4 This technology aims to predict drug efficacy and toxicity before clinical trials, potentially streamlining the drug development process.2

Prior to founding SynTensor, Rabideau was a PhD candidate at the University of Cambridge from September 2016 to September 2020.1 His academic background and research focus have directly influenced the development of SynTensor's innovative approach to drug discovery and development.

Highlights

Aug 15 · crowdonomics.co
Syntensor - Company Profile - Crowdonomics
Aug 1 · kingscrowd.com
Syntensor on Republic 2024 - Kingscrowd
Jan 1 · syntensor.com
About us - Syntensor
About us - Syntensor
Jan 1 · syntensor.com
Syntensor
Jan 1 · syntensor.com
Syntensor Inc
SYNTENSOR LTD. overview - Find and update company information

Related Questions

What inspired Clayton Rabideau to start SynTensor?
How does SynTensor's platform work in predicting drug efficacy?
What are some of the challenges Clayton Rabideau has faced as CEO of SynTensor?
How does SynTensor's technology compare to other drug discovery platforms?
What are the future plans for SynTensor under Clayton Rabideau's leadership?
Clayton Rabideau
Clayton Rabideau, photo 1
Clayton Rabideau, photo 2
Add to my network

Location

United States